- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04820569
Long-term Heart-specific Mortality in the Presence of Competing Risks Among Patients With Non-metastatic Gastric Adenocarcinoma Undergoing Resection and Chemotherapy (GaCCoR-01)
March 25, 2021 updated by: Lei Huang, The First Affiliated Hospital of Anhui Medical University
Long-term Heart-specific Mortality in the Presence of Competing Risks Among Patients With Non-metastatic Gastric Adenocarcinoma Undergoing Resection and Chemotherapy A Population-based Cohort Study of 21,257 Cases, 2004-2016
In this population-based cohort study, data on patients diagnosed with nmGaC in 2004 through 2016, managed with resection and chemotherapy, followed up until the end of 2016, and surviving ≥1 month were retrieved from the US Surveillance, Epidemiology, and End Results-18 Program.
Cumulative mortality functions were calculated.
Prognostic factors for heart-specific mortality were evaluated using both multivariable-adjusted Fine-Gray subdistribution and cause-specific hazard functions.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
21257
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Cases of non-metastatic gastric adenocarcinoma (nmGaC) were defined as patients with microscopically-confirmed first primary invasive adenocarcinoma of the stomach (International Classification of Diseases for Oncology, Third Edition (ICD-O-3) code: C16) without distant metastasis.
Only those who underwent resection in January 2004 through December 2016 were included.
Description
Cases of non-metastatic gastric adenocarcinoma (nmGaC) were defined as patients with microscopically-confirmed first primary invasive adenocarcinoma of the stomach (International Classification of Diseases for Oncology, Third Edition (ICD-O-3) code: C16) without distant metastasis.
Only those who underwent resection in January 2004 through December 2016 were included.
Cancers of other histology types including squamous cell carcinoma, gastrointestinal stromal tumor or sarcoma, neuroendocrine tumor or carcinoid, lymphoma, and germ-cell tumor were ineligible, as were patients with non-gastric cancers involving the stomach, with benign or in situ tumors, or with other malignancies before gastric cancer.
We further excluded patients with diagnosis based on death certificate only or autopsy, with missing follow-up period, survival status, or cause of death, or with unknown metastasis status.
Cancers with distant metastasis were excluded since resection is not routinely recommended for them.
Data before 2004 were not included, as the TNM stage information was unavailable.
To minimize the effect of perioperative events on survival, we excluded patients surviving <1 month.
No restrictions were applied to age, and patients ≥80 years only comprised 5% of those receiving both resection and chemotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative mortality
Time Frame: Jan 12, 2020-Mar 5, 2021
|
Cumulative incidence functions (CIFs), which, unlike the standard Kaplan-Meier method, allow for estimation of the incidence of the occurrence of an event while taking competing risks from other causes of death into account, were computed and plotted for cause-specific mortalities.
|
Jan 12, 2020-Mar 5, 2021
|
Prognostic factors for disease-specific mortalities
Time Frame: Jan 12, 2020-Mar 5, 2021
|
Evaluated using both multivariable-adjusted Fine-Gray subdistribution and cause-specific hazard functions.
|
Jan 12, 2020-Mar 5, 2021
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2004
Primary Completion (Actual)
December 31, 2016
Study Completion (Actual)
December 31, 2016
Study Registration Dates
First Submitted
March 25, 2021
First Submitted That Met QC Criteria
March 25, 2021
First Posted (Actual)
March 29, 2021
Study Record Updates
Last Update Posted (Actual)
March 29, 2021
Last Update Submitted That Met QC Criteria
March 25, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GaCCoR-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
The Surveillance, Epidemiology, and End Results Program data are available upon reasonable request and with permission of the registry.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Resection and chemotherapy
-
Fundación de Investigación Biomédica - Hospital...Marcello Di MartinoCompletedMetastatic Colorectal Cancer | Metastatic Liver CancerSpain, United Kingdom, France
-
Università Vita-Salute San RaffaeleCompletedLocally Advanced Pancreatic AdenocarcinomaItaly
-
University of MaltaCompletedQuality of Life | Cancer | Low Anterior Resection SyndromeMalta
-
Region SkaneRecruitingMetastatic Colorectal Cancer | Lung Metastases | Chemotherapy Effect | Peritoneal Metastases | Liver Metastasis Colon CancerSweden
-
Beijing Stomatological HospitalBeijing Friendship Hospital; Beijing Chao Yang Hospital; The First Affiliated... and other collaboratorsRecruitingQuality of Life | Postoperative Complications | Head and Neck NeoplasmsChina
-
Menoufia UniversityWithdrawnOvarian Cancer | Recurrent Ovarian CarcinomaEgypt
-
Yonsei UniversityTerminated
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityUnknown
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingColorectal Cancer | Chemotherapy Effect | Liver Metastases | Circulating Tumor CellChina
-
Henan Cancer HospitalUnknownAdenocarcinoma of the Stomach / GastroesophagealChina